With the introduction of its generic Semaglutide under the brand “SUNDAE” in India, Eris Lifesciences Limited (“Eris Lifesciences” or the “Company”) (BSE: 540596; NSE: ERIS), a prominent Indian branded formulations company, announced a significant step in increasing access to advanced diabetes care. Eris is launching SUNDAE in multi-dose vial formats at extremely affordable prices, beginning at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants, demonstrating its dedication as a responsible stakeholder in addressing the nation’s rising diabetes burden. Nearly 70% of India’s diabetes patients will now be able to afford effective GLP-1 therapy thanks to this launch.

Additionally, the company intends to increase patient convenience and adoption by launching a pen-device version in April that will cost INR 4,000, INR 4,200, and INR 4,500 per month for the strengths of 2 mg/1.5 ml, 4 mg/3 ml, and 8 mg/3 ml, respectively.

Strong results in glycemic control and weight loss have made semaglutide, a GLP-1 receptor agonist, a game-changing treatment for Type 2 diabetes and weight management. GLP-1 therapies offer a substantial growth opportunity given India’s rapidly expanding diabetic population and growing obesity awareness.

Through close collaboration with experts throughout India, Eris has made a significant impact in the field of diabetology. Its advanced diabetes portfolio is strengthened, and its role in next-generation metabolic care is expanded with the addition of semaglutide.

“Semaglutide represents a breakthrough in the management of diabetes and metabolic disorders, with the potential to significantly improve patient outcomes. With the introduction of SUNDAE, we are carrying out our duty to provide such cutting-edge treatments to a much greater number of patients at a reasonable cost. This demonstrates our ongoing dedication to bolstering our diabetes portfolio with patient-centered, high-impact solutions while utilizing our robust position in chronic care to accelerate adoption and increase access throughout India,” said the company.

Priyanka Dutta